Jubilant Pharmova directors resign to join subsidiary Jubilant Biosys

Jubilant Pharmova Limited announced on September 1, 2025, the resignations of Dr. Ramakrishnan Arul, whole-time director, and Dr. Tushar Gupta, chief of operations for the Contract Research, Development, and Manufacturing Organization (CRDMO) business. Both resignations are effective from the close of business on August 31, 2025.

These executive changes follow the previously disclosed sale and transfer of the company’s Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary. Both Dr. Arul and Dr. Gupta are transferring to Jubilant Biosys Limited, where they will assume new responsibilities effective September 1, 2025, as part of the strategic restructuring of the API business.

The company affirmed that these disclosures comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated November 11, 2024.